PW Medtech Group Limited (01358.HK) is a leading medical device company in China focusing on high growth, high margin products with strong market demand. Its existing businesses include orthopedic implants and advanced infusion sets, with leading positions in both segments. The company has an experienced management team and a nationwide distribution network covering 30 provinces, with high penetration of advanced infusion sets in first-tier cities, and a focus on second- and third-tier cities for its orthopedic portfolio.
Warburg Pincus supported PW MedTech's strategic acquisitions of three companies – Weiman, Fert and BoneMed – to become a leading player in the orthopedic implant and advanced infusion set markets in China. In 2013, the company completed an IPO on the Hong Kong Stock Exchange, raising $188 million.
Back to Previous Page